Trial · NCT06736353
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Composite | From enrollment (hospital discharge after type 2 MI) until Composite endpoint, Loss to follow-up or End of follow up (date of data collection: 05-May-2022) | Composite endpoint: All-cause mortality, readmission for MI, stroke or heart failure |
| Secondary | All-cause mortality | From enrollment (hospital discharge after type 2 MI) until Death, Loss to follow-up or End of follow up (date of data collection: 05-May-2022) | Death from any cause |
| Secondary | Cardiovascular mortality | From enrollment (hospital discharge after type 2 MI) until Cardiovascular death, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied. | Death from cardiovascular disease |
| Secondary | Readmission for MI | From enrollment (hospital discharge after type 2 MI) until Readmission for MI, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied. | Readmission for myocardial infarction |
| Secondary | Readmission for stroke | From enrollment (hospital discharge after type 2 MI) until Readmission for Stroke, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied. | Readmission for stroke |
| Secondary | Readmission for heart failure | From enrollment (hospital discharge after type 2 MI) until Readmission for Heart failure, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied. | Readmission for heart failure |
| Other | Readmission for Asthma or COPD | From enrollment (hospital discharge after type 2 MI) until Readmission for Asthma/COPD, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied. | Safety outcome in Beta blocker target trial emulation. Readmission for Asthma or Chronic Obstructive Pulmonary Disease. Only if main diagnosis. |
| Other | Readmission for Acute renal failure | From enrollment (hospital discharge after type 2 MI) until Readmission for Acute renal failure, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied. | Safety outcome in RAAS blocker target trial emulation. Readmission for Acute renal failure. |
| Other | Readmission for bleeding | From enrollment (hospital discharge after type 2 MI) until Readmission for Bleeding, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied. | Safety outcome in SAPT and DAPT target trial emulations. Readmission for bleeding. |
| Other | Readmission for Pneumonia | From enrollment (hospital discharge after type 2 MI) until Readmission for bacterial pneumonia, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied. | Negative control outcome in all target trial emulations. Readmission for bacterial pneumonia. |
| Other | Readmission for hip fracture | From enrollment (hospital discharge after type 2 MI) until Readmission for hip fracture, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied. | Additional negative control outcome in all target trial emulations. Readmission for hip fracture. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06736353/registered